December 14, 2010 10:08 ET

Sales for New Cancer Drugs Exceeded $1 Billion

ROCKVILLE, MD--(Marketwire - December 14, 2010) - has announced the addition of Espicom Healthcare Intelligence's new report "Cancer Drug Blockbusters," to their collection of Biopharmaceuticals market reports. For more information, visit

The pursuit of safe and effective cancer medicines dominates research funding and the sector has more blockbuster products than any other therapy area.

There exists a huge variety of cancer treatments, from the widely-used chemotherapeutic agents to the recently-launched, first-in-class cancer vaccine, with many of these treatments achieving blockbuster sales in excess of US$1 billion. However, many existing brands face declining sales due to generic erosion as patents expire, and the rate at which new drugs reach the market is slowing, impacting company revenues.

This report identifies the current oncology blockbuster products and assesses their future market potential, looking at both winners and losers in the competitive landscape to 2016. In addition, it highlights the promising products that, in Espicom's analysis, will successfully carve out a market share to become the oncology blockbusters of the future. Both current and future marketplaces are analyzed from the companies' perspective, identifying the products on which their relative success or failure rests.

All 21 products featured in this report are also detailed and analyzed individually in terms of their current status, mode of action, clinical data, risks associated with their development, expertise of developing/marketing company and the competitive pressures they may face. This analysis is summarized in the form of a unique score that acts as a useful comparative tool and 7-year individual product forecasts are provided to 2016.

For more information, visit

Contact Information